Our study hypothesis is as follows: if IC/BPS bladders present with increased expression of VEGF, agents that affect VEGF or VEGFR expression/activation would have a therapeutic effect in such patients. This evidence concerns the gene KDR and Bartsocas-Papas syndrome 1.